Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Clinical Trials

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Phase 2

Completed

Conditions: Neutropenia
Sarcoma

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2003-06-18

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00002643

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States

and more 46 locations

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Phase 2

Completed

Conditions: Peritoneal Cancer
Ovarian Cancer
Neoplasms, Ovarian
Fallopian Tube Cancer

First Posted Date: 2003-05-28

Last Posted Date: 2017-06-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 75

Registration Number: NCT00061308

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Drug: Topotecan

First Posted Date: 2003-05-07

Last Posted Date: 2012-09-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 41

Registration Number: NCT00005793

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer

First Posted Date: 2003-04-18

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003064

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia

Phase 1

Completed

Conditions: Leukemia
Neutropenia

First Posted Date: 2003-04-11

Last Posted Date: 2011-08-03

Lead Sponsor: Mayo Clinic

Registration Number: NCT00002693

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Biological: G-CSF
Drug: Cisplatin
Drug: Irinotecan
Drug: Etoposide
Drug: Topotecan

First Posted Date: 2003-04-09

Last Posted Date: 2023-07-05

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 140

Registration Number: NCT00057837

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States

and more 75 locations

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Neoplasms

First Posted Date: 2003-04-08

Last Posted Date: 2011-07-25

Lead Sponsor: Telik

Target Recruit Count: 440

Registration Number: NCT00057720

Locations: 🇺🇸
The Center for Hematology-Oncology, Delray Beach, Florida, United States
🇺🇸
Dallas Oncology Consultants, Dallas, Texas, United States
🇺🇸
Texas Cancer Associates, Dallas, Texas, United States

and more 267 locations

Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2013-06-26

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 20

Registration Number: NCT00055614

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer

Phase 1

Completed

Conditions: Stage III Cervical Cancer
Stage IVA Cervical Cancer
Cervical Squamous Cell Carcinoma
Stage IB Cervical Cancer
Stage IIA Cervical Cancer
Stage IIB Cervical Cancer
Cervical Adenocarcinoma

Interventions: Drug: Topotecan Hydrochloride Liposomes
Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Cisplatin

First Posted Date: 2003-02-06

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 11

Registration Number: NCT00054444

Locations: 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 7 locations

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Phase 2

Completed

Conditions: Myelodysplastic/Myeloproliferative Diseases
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-28

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT00053287

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy